# **PCT**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent classification <sup>6</sup> :	 	(11)	International publication number: WO 98/48836
A61K 39/106	<b>A</b> 1	(43)	International publication date:
			5 November 1998 (05.11.98)

- (21) International application number: PCT/FR98/00875
- (22) International filing date: 30 April 1998 (30.04.98)
- (30) Data relating to the priority:

97/05,608 30 April 1997 (30.04.97) FR 97/15,732 8 December 1997 (08.12.97) FR

- (71) Applicant (for all designated States except US):

  MERIEUX ORAVAX [FR/FR]; 58, avenue Leclerc,
  F-69007 Lyon (FR).
- (72) Inventors; and
- (75) Inventors/Applicants (US only): Bruno GUY [FR/FR]; 15B, rue des Noyer, F-69005 Lyon (FR). Jean HAENSLER [FR/FR]; "Les Bullandières" Bâtiment B, 17, rue Piccandet, F-69290 Saint Genis les Ollières (FR).
- (74) Representative: Marie-Pauline AYROLES; Pasteur Mérieux Sérums & Vaccins, Industrial Property Directorate, 58, avenue Leclerc, F-69007 Lyon (FR).

(81) Designated states: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO Patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

#### **Published**

With the International Search Report.

Before expiry of the period provided for amending the claims, will be republished if such amendments are received.

### As printed

- (54) Title: ANTI-HELICOBACTER VACCINE COMPOSITION COMPRISING A THI ADJUVANT
- (54) Titre: COMPOSITION VACCINALE ANTI-HELICOBACTER COMPRENANT UN ADJUVANT DE TYPE THI
- (57) Abstract

The invention concerns the use of an immunogenic agent derived from *Helicobacter*, associated with an adjuvant such as QS-21, DC-chol or Bay R1005, for making a pharmaceutical composition designed to induce an immune response of the T helper 1 type (Th1), for preventing or treating *Helicobacter* infection in a mammal.

#### (57) Abrégé

L'invention a pour objet l'usage d'un agent immunogène dérivé d'Helicobacter, en association avec un adjuvant tel que le QS-21, le DC-chol ou le Bay R1005, dans la fabrication d'une composition pharmaceutique destinée à l'induction d'une réponse immune de type T helper 1 (Th1) à l'encontre d'Helicobacter, pour prévenir ou traiter une infection à Helicobacter chez un mammifère.